Please read and agree to the terms and conditions of this site.
@xconomy.com 4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com 4 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com 4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com 5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com 5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com 5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com 5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com 5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com 6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M